ALK gene copy number gain and its clinical significance in hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 20, Issue 1, 2014, Pages 183-192

  Jia, Shou Wei ^a   Fu, Sha ^a   Wang, Fang ^a   Shao, Qiong ^a   Huang, Hong Bing ^a   Shao, Jian Yong ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Anaplastic lymphoma kinase gene; Hepato cellular carcinoma; Prognostic predictor

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE;

ADULT; AGED; ALK GENE; ALLELE; ARTICLE; CHROMOSOME TRANSLOCATION; COPY NUMBER VARIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE FREQUENCY; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TISSUE MICROARRAY;

ANAPLASTIC LYMPHOMA KINASE GENE; HEPATOCELLULAR CARCINOMA; PROGNOSTIC PREDICTOR;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA COPY NUMBER VARIATIONS; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; RECEPTOR PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84891767551     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i1.183     Document Type: Article

References (41)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]
2. Yang Y, Lu Y, Wang C, Bai W, Qu J, Chen Y, Chang X, An L, Zhou L, Zeng Z, Lou M, Lv J. Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Exp Ther Med 2012; 3: 171-180 [PMID: 22969864 DOI: 10.3892/etm]
3. Baek YH, Kim KT, Lee SW, Jeong JS, Park BH, Nam KJ, Cho JH, Kim YH, Roh YH, Lee HS, Choi YM, Han SY. Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. World J Gastroenterol 2012; 18: 3426-3434 [PMID: 22807613 DOI: 10.3748/wjg.v18.i26.3426]
4. Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, Montalto G. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 2012; 3: 236-260 [PMID: 22470194]
5. Tanaka S, Arii S. Molecular targeted therapies in hepatocellular carcinoma. Semin Oncol 2012; 39: 486-492 [PMID: 22846865 DOI:10.1053/j.seminoncol]
6. Frenette C, Gish R. Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications. World J Gastroenterol 2012; 18: 498-506 [PMID: 22363115 DOI: 10.3748/wjg.v18.i6.498]
7. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566 [PMID: 17625570 DOI: 10.1038/nature05945]
8. Murakami Y, Mitsudomi T, Yatabe Y. A Screening Method for the ALK Fusion Gene in NSCLC. Front Oncol 2012; 2: 24 [PMID: 22655265]
9. Vincent MD, Kuruvilla MS, Leighl NB, Kamel-Reid S. Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS. Curr Oncol 2012; 19: S33-S44 [PMID: 22787409 DOI: 10.3747/co.19.1149]
10. Sasaki T, Rodig SJ, Chirieac LR, Jänne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010; 46: 1773-1780 [PMID: 20418096 DOI: 10.1016/ j.ejca.2010.04.002]
11. Ou SH. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther 2011; 5: 471-485 [PMID: 22162641 DOI: 10.2147/DDDT.S19045]
12. Mossé YP, Wood A, Maris JM. Inhibition of ALK signaling for cancer therapy. Clin Cancer Res 2009; 15: 5609-5614 [PMID: 19737948]
13. Kutok JL, Aster JC. Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. J Clin Oncol 2002; 20: 3691-3702 [PMID: 12202671 DOI: 10.1200/ JCO.2002.12.033]
14. George RE, Sanda T, Hanna M, Fröhling S, Luther W, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, Xue L, Zozulya S, Gregor VE, Webb TR, Gray NS, Gilliland DG, Diller L, Greulich H, Morris SW, Meyerson M, Look AT. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008; 455: 975-978 [PMID: 18923525 DOI: 10.1038/nature07397]
15. Pulford K, Lamant L, Espinos E, Jiang Q, Xue L, Turturro F, Delsol G, Morris SW. The emerging normal and diseaserelated roles of anaplastic lymphoma kinase. Cell Mol Life Sci 2004; 61: 2939-2953 [PMID: 15583856]
16. Lastowska M, Viprey V, Santibanez-Koref M, Wappler I, Peters H, Cullinane C, Roberts P, Hall AG, Tweddle DA, Pearson AD, Lewis I, Burchill SA, Jackson MS. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data. Oncogene 2007; 26: 7432-7444 [PMID: 17533364 DOI: 10.1038/sj.onc.1210552]
17. Salido M, Pijuan L, Martínez-Avilés L, Galván AB, Cañadas I, Rovira A, Zanui M, Martínez A, Longarón R, Sole F, Serrano S, Bellosillo B, Wynes MW, Albanell J, Hirsch FR, Arriola E. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol 2011; 6: 21-27 [PMID: 21107285 DOI: 10.1097/ JTO.0b013e3181fb7cd6]
18. Schoppmann SF, Streubel B, Birner P. Amplification but not translocation of anaplastic lymphoma kinase is a frequent event in oesophageal cancer. Eur J Cancer 2013; 49: 1876-1881 [PMID: 23490651 DOI: 10.1016/j.ejca.2013.02]
19. Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, Laureys G, Speleman F, Kim C, Hou C, Hakonarson H, Torkamani A, Schork NJ, Brodeur GM, Tonini GP, Rappaport E, Devoto M, Maris JM. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455: 930-935 [PMID: 18724359]
20. Carén H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 2008; 416: 153-159 [PMID: 18990089]
21. Holm C, Rayala S, Jirström K, Stål O, Kumar R, Landberg G. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst 2006; 98: 671-680 [PMID: 16705121 DOI: 10.1093/jnci/djj185]
22. Wang HY, Li YY, Shao Q, Hou JH, Wang F, Cai MB, Zeng YX, Shao JY. Secreted protein acidic and rich in cysteine (SPARC) is associated with nasopharyngeal carcinoma metastasis and poor prognosis. J Transl Med 2012; 10: 27 [PMID: 22321704 DOI: 10.1186/1479-5876-10-27]
23. Thunnissen E, Bubendorf L, Dietel M, Elmberger G, Kerr K, Lopez-Rios F, Moch H, Olszewski W, Pauwels P, PenaultLlorca F, Rossi G. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch 2012; 461: 245-257 [PMID: 22825000 DOI: 10.1007/s00428]
24. Bang YJ. The potential for crizotinib in non-small cell lung cancer: a perspective review. Ther Adv Med Oncol 2011; 3: 279-291 [PMID: 22084642]
25. Soda M, Isobe K, Inoue A, Maemondo M, Oizumi S, Fujita Y, Gemma A, Yamashita Y, Ueno T, Takeuchi K, Choi YL, Miyazawa H, Tanaka T, Hagiwara K, Mano H. A prospective PCR-based screening for the EML4-ALK oncogene in nonsmall cell lung cancer. Clin Cancer Res 2012; 18: 5682-5689 [PMID: 22908099 DOI: 10.1158/1078-0432.CCR-11-2947]
26. Li YH, Wang F, Shen L, Deng YM, Shao Q, Feng F, An X, Wang FH, Wang ZQ, Xu RH, Shao JY. EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients. Clin Cancer Res 2011; 17: 382-390 [PMID: 20884623 DOI: 10.1158/1078-0432.CCR-10-0208]
27. Shiraha H, Yamamoto K, Namba M. Human hepatocyte carcinogenesis (review). Int J Oncol 2013; 42: 1133-1138 [PMID: 23426905 DOI: 10.3892/ijo.2013.1829]
28. Takahashi T, Sonobe M, Kobayashi M, Yoshizawa A, Menju T, Nakayama E, Mino N, Iwakiri S, Sato K, Miyahara R, Okubo K, Manabe T, Date H. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 2010; 17: 889-897 [PMID: 20183914]
29. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957 [PMID: 19692680 DOI: 10.1056/NEJMoa0810699]
30. Motegi A, Fujimoto J, Kotani M, Sakuraba H, Yamamoto T. ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth. J Cell Sci 2004; 117: 3319-3329 [PMID: 15226403 DOI: 10.1242/jcs.01183]
31. Jawhar NM. Tissue Microarray: A rapidly evolving diagnostic and research tool. Ann Saudi Med 2009; 29: 123-127 [PMID: 19318744 DOI: 10.4103/0256-4947]
32. Fukuyoshi Y, Inoue H, Kita Y, Utsunomiya T, Ishida T, Mori M. EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers. Br J Cancer 2008; 98: 1536-1539 [PMID: 18414414 DOI: 10.1038/sj.bjc.6604341]
33. Miyake I, Hakomori Y, Shinohara A, Gamou T, Saito M, Iwamatsu A, Sakai R. Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene 2002; 21: 5823-5834 [PMID: 12185581 DOI: 10.1038/sj.onc.1205735]
34. Azarova AM, Gautam G, George RE. Emerging importance of ALK in neuroblastoma. Semin Cancer Biol 2011; 21: 267-275 [PMID: 21945349 DOI: 10.1016/j.semcancer.2011.09.005]
35. Janoueix-Lerosey I, Lequin D, Brugières L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, Valteau-Couanet D, Frebourg T, Michon J, Lyonnet S, Amiel J, Delattre O. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008; 455: 967-970 [PMID: 18923523 DOI: 10.1038/nature07398]
36. Grande E, Bolós MV, Arriola E. Targeting oncogenic ALK: a promising strategy for cancer treatment. Mol Cancer Ther 2011; 10: 569-579 [PMID: 21474455 DOI: 10.1158/1535-7163. MCT-10-0615]
37. Preusser M, Berghoff AS, Ilhan-Mutlu A, Magerle M, Dinhof C, Widhalm G, Dieckmann K, Marosi C, Wöhrer A, Hackl M, Zöchbauer-Müller S, von Deimling A, Schoppmann SF, Zielinski CC, Streubel B, Birner P. ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. Lung Cancer 2013; 80: 278-283 [PMID: 23453647]
38. Tuma RS. ALK gene amplified in most inflammatory breast cancers. J Natl Cancer Inst 2012; 104: 87-88 [PMID: 22215853 DOI: 10.1093/jnci/djr553]
39. De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, Lakeman A, Vandesompele J, Hoebeeck J, Van Maerken T, De Paepe A, Laureys G, Schulte JH, Schramm A, Van Den Broecke C, Vermeulen J, Van Roy N, Beiske K, Renard M, Noguera R, Delattre O, JanoueixLerosey I, Kogner P, Martinsson T, Nakagawara A, Ohira M, Caron H, Eggert A, Cools J, Versteeg R, Speleman F. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 2010; 16: 4353-4362 [PMID: 20719933 DOI: 10.1158/1078-0432.CCR-09-2660]
40. Shao CK, Su ZL, Feng ZY, Rao HL, Tang LY. Significance of ALK gene expression in neoplasms and normal tissues. Ai Zheng 2002; 21: 58-62 [PMID: 12500399]
41. Bagci O, Tumer S, Olgun N, Altungoz O. Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors. Cancer Lett 2012; 317: 72-77 [PMID: 22085494 DOI: 10.1016/ j.canlet.2011.11.013]